Rifampin is an antibiotic used to treat bacterial infections, most commonly tuberculosis and leprosy. It works by killing bacteria that cause these serious infections.[2] Rifadin is currently approved and in use across 49 indications[4].[1]
Rifadin is one of 944 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
1774 competitors in Lymphoma
Rifadin
Velban
Oncaspar
Wellcovorin
Tafasitamab
Nuvigil
Elitek
Systemic Therapy
Rhg-CSF
CAR-T
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
RIFADIN
NDA NDA050420
Jan 1, 1982
RIMACTANE
NDA NDA050429
May 25, 1989
RIFADIN
NDA NDA050627
Sources